Our results showed that PE-conjugated anti-PD-L1 binding to PD-L1 on live cancer cells was significantly blocked in the CF33-hNIS-antiPDL1-treated cells compared with both PBS control and CF33-GFP (p < 0.01, respectively, Figure 4B). The gene discussed is CD274; the disease is cancer.